- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06226610
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will receive six injections of Dupixent or placebo (two 300 mg loading doses and one 300 mg dose every two weeks after that).
In addition, they will be asked to complete questionnaires to determine daily itch severity, quality of life, treatment benefit, physical functioning, and pain interference.
Individual participants will require 13 weeks to complete all study visits.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: ANJAY KHANDELWAL, MD
- Phone Number: 330-543-4649
- Email: akhandelwal@akronchildrens.org
Study Contact Backup
- Name: Jo Ann Katz, BSN
- Phone Number: 330-543-0690
- Email: jkatz@akronchildrens.org
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Persons 18-60 year old with post-burn hypertrophic scars of any size which required grafting or epidermal autografting for an acute burn injury, with continued complaint of pruritus due to inadequate relief from standard of care (medical management by antihistamine and neuroleptic medications) after at least four weeks and are a minimum of four weeks after their last grafting surgery, and who speak English sufficient to participate in the study.
Exclusion Criteria:
- Currently taking Dupixent for any other diagnosis
- known allergy to Dupixent
- pregnant and or lactating mothers
- anyone treated for pruritus using laser therapy
- currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications
- Currently taking steroids
- persons with developmental delays or otherwise unable to complete measures
- prisoners or anyone otherwise unable to give their own consent or who is not their own guardian
- one or more of the following existing disorders: conjunctivitis; any co-existing dermatological condition except burns; any type of cancer; requiring dialysis; chronic Stage 3 or higher kidney disease; biliary disorder; gall bladder disorder; or another renal or hepatic disorder which, in the opinion of study physician, deems this study inappropriate for an eligible individual.
- Persons unable to provide their own consent, including prisoners when their incarcerated status is not itself the focus of study, are routinely excluded from clinical trials at this site
- We further exclude persons with other dermatological conditions (other than burn) , which may have pruritis or pain associated with them and who may be treated with medications other than Dupixent, and whose perceived benefit could confound our results.
- We similarly exclude anyone treated for pruritis by laser therapy as their perceived benefit could confound our results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ARM 1 - Dupixent
Two subcutaneous injection of 300mg Dupixent at visit 1 and every two weeks (+/- 2 days) for a total of 6 administrations.
Injections may be administered in the thigh, lower abdomen or upper arm.
The initial dose (two 300 mg doses) will be given in two different injection sites.
There are not restriction or guidance regarding dose administration related to meals.
No dose modifications will occur during study participation.
|
injection every two weeks while on study
|
Placebo Comparator: ARM 2 - Placebo
Two subcutaneous injection of the placebo at visit 1 and every two weeks (+/- 2 days) for a total of 6 administrations.
Injections may be administered in the thigh, lower abdomen or upper arm.
The initial dose (two doses) will be given in two different injection sites.
There are not restriction or guidance regarding dose administration related to meals.
No dose modifications will occur during study participation.
|
injection every two weeks while on study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ITCH SEVERITY SCALE SCORES
Time Frame: 12 WEEKS
|
participants' Itch Severity Scale (ISS) scores will decrease more than 2.0 points after 12 weeks following initiating use of Dupixent
|
12 WEEKS
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pruritis
-
Alexandria UniversityRecruitingRefractory Uremic PruritisEgypt
-
Letterkenny General HospitalCompletedAcupuncture | Morphine Induced PruritisIreland
-
Wake Forest UniversityStiefel, a GSK CompanyCompleted
-
Tanta UniversityCompleted
-
University of British ColumbiaCompleted
-
Washington University School of MedicineWithdrawn
-
Mansoura UniversityUnknownMagnesium Infusion in Post-spinal Opioid PruritisEgypt
-
Winthrop University HospitalNational Kidney FoundationCompletedPruritisUnited States
-
Kiniksa Pharmaceuticals, Ltd.CompletedPrurigo Nodularis | PruritisUnited States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Poland, Taiwan, United Kingdom
Clinical Trials on Dupilumab
-
SanofiRegeneron PharmaceuticalsNot yet recruiting
-
Brigham and Women's HospitalRegeneron PharmaceuticalsRecruiting
-
University of MichiganRegeneron PharmaceuticalsRecruiting
-
Northwestern UniversityRecruitingSkin DiseasesUnited States
-
SanofiRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolyposisFrance, Réunion
-
University of California, San FranciscoRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAsthma; EosinophilicSpain
-
Montefiore Medical CenterRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Erasmus Medical Center; Prothya BiosolutionsRecruitingAtopic Dermatitis | Atopic Dermatitis EczemaNetherlands